^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DNAJB1-PRKACA peptide vaccine

    i
    Associations
    News

    Trials

    Company:
    BMS, Sidney Kimmel Comprehensive Cancer Center
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA (FusionVAC22_02) (NCT06789198)
    Phase 1
    University Hospital Tuebingen
    Not yet recruiting
    Last update posted :
    01/28/2025
    Initiation :
    04/01/2025
    Primary completion :
    11/01/2028
    Completion :
    11/01/2028
    IFNG
    |
    DNAJB1-PRKACA peptide vaccine • Fusion-VAC-XS15
    DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma (NCT04248569)
    Phase 1
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    06/07/2024
    Initiation :
    04/20/2020
    Primary completion :
    03/01/2027
    Completion :
    03/01/2027
    CD8 • CD4 • DNAJB1 • PRKACA
    |
    DNAJB1-PRKACA fusion
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • DNAJB1-PRKACA peptide vaccine • Hiltonol (poly-ICLC)
    FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition (NCT05937295)
    Phase 1
    University Hospital Tuebingen
    Recruiting
    Last update posted :
    09/29/2023
    Initiation :
    09/26/2023
    Primary completion :
    09/01/2026
    Completion :
    01/01/2027
    DNAJB1 • PRKACA
    |
    DNAJB1-PRKACA fusion
    |
    Tecentriq (atezolizumab) • DNAJB1-PRKACA peptide vaccine • Fusion-VAC-XS15